NASDAQ:AIKI AIkido Pharma (AIKI) Stock Price, News & Analysis $2.00 -0.01 (-0.25%) As of 01/28/2025 Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsFinancialsInsider TradesSEC FilingsTrends About AIkido Pharma Stock (NASDAQ:AIKI) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get AIkido Pharma alerts:Sign Up Key Stats Today's Range$1.73▼$2.0550-Day Range$0.90▼$3.5652-Week Range$3.31▼$11.48Volume274,907 shsAverage Volume79,326 shsMarket Capitalization$10.94 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewAIkido Pharma Inc., a biotechnology company, focuses on developing small-molecule anti-cancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The company is also developing an antiviral platform that inhibits replication of viruses, including influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2. It has license agreements with the University of Texas, University of Maryland Baltimore, Silo Pharma Inc., and Wake Forest University Health Sciences. The company was formerly known as Spherix Incorporated and changed its name to AIkido Pharma Inc. in March 2021. AIkido Pharma Inc. was founded in 1967 and is headquartered in New York, New York.Read More… Receive AIKI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AIkido Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address AIKI Stock News HeadlinesSNOA Sonoma Pharmaceuticals, Inc.March 17, 2024 | seekingalpha.comRoyalty Pharma PLCJanuary 23, 2024 | wsj.comGrab This Altcoin Before Trump's Crypto AnnouncementThe #1 Coin Poised to Soar Under Trump Pro-Crypto White House could make this the investment opportunity of a lifetime! January 30, 2025 | Crypto 101 Media (Ad)Kengan Ashura: 10 Strongest Fighters, RankedOctober 6, 2023 | msn.comDominari Holdings Inc. Releases Shareholder UpdateSeptember 6, 2023 | markets.businessinsider.comKyle Wool Appears on Fox BusinessApril 10, 2023 | markets.businessinsider.comDominari Holdings Appoints George Way As CFOApril 3, 2023 | markets.businessinsider.comDominari Financial Inc. Acquires Leading Broker Dealer and Registered Investment Advisor BusinessMarch 27, 2023 | markets.businessinsider.comSee More Headlines AIKI Stock Analysis - Frequently Asked Questions How have AIKI shares performed this year? AIkido Pharma's stock was trading at $0.9844 at the start of the year. Since then, AIKI stock has increased by 102.7% and is now trading at $1.9950. View the best growth stocks for 2025 here. When did AIkido Pharma's stock split? Shares of AIkido Pharma reverse split on Tuesday, June 7th 2022. The 1-17 reverse split was announced on Tuesday, June 7th 2022. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, June 7th 2022. An investor that had 100 shares of stock prior to the reverse split would have 6 shares after the split. Does AIkido Pharma have any subsidiaries? The following companies are subsidiaries of AIkido Pharma: Hoth Therapeutics. How do I buy shares of AIkido Pharma? Shares of AIKI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of AIkido Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that AIkido Pharma investors own include Atossa Therapeutics (ATOS), iBio (IBIO), Bionano Genomics (BNGO), Ocugen (OCGN), Meta Platforms (META), Cineverse (CNVS) and Company Calendar Today1/30/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Commercial physical research Sub-IndustryN/A Current SymbolNASDAQ:AIKI CUSIPN/A CIK12239 Webwww.spherix.com Phone(112) 745-1374Fax703-992-9348Employees4Year Founded1967Profitability EPS (Most Recent Fiscal Year)($3.88) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-7,170,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-18.21% Return on Assets-16.94% Debt Debt-to-Equity RatioN/A Current Ratio29.54 Quick Ratio29.54 Sales & Book Value Annual Sales$10,000.00 Price / Sales1,094.26 Cash FlowN/A Price / Cash FlowN/A Book Value$19.27 per share Price / Book0.10Miscellaneous Outstanding Shares5,485,000Free Float5,013,000Market Cap$10.94 million OptionableNot Optionable Beta0.93 Social Links Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free Report This page (NASDAQ:AIKI) was last updated on 1/30/2025 by MarketBeat.com Staff From Our PartnersTexas approves new currencyRural Texas Town Ramps Up Global Currency War A small town has joined a radical $1.9 trillion attack on the...Stansberry Research | SponsoredIs Big Tech dead?China just threw a “$5.5 million” curveball called Deep Seek to Silicon Valley and the timing of it is no coin...Brownstone Research | SponsoredElon’s ultimate power move?THE ELON SHOCK All of Elon Musk’s strange behavior may soon make sense… and impact the markets in a way no ...Altimetry | SponsoredDonald Trump is about to free crypto from its chains …On October 25th, Juan said Bitcoin would cross $100,000 before the inauguration. Now he thinks it could rea...Weiss Ratings | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredPlease take this warning seriously...I’m here to issue a stark warning to you about an unexpected $2 trillion shock that could impact every trader ...Timothy Sykes | SponsoredHot Stock Alert! Biotech innovator on the NYSE announces breakthrough antiviral therapyA revolutionary antiviral drug is here! This breakthrough could mean viruses are unlikely to escape treatment....Smallcaps Daily | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AIkido Pharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AIkido Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.